Evidences of Histologic Thrombotic Microangiopathy and the Impact in Renal Outcomes of Patients with IgA Nephropathy

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2020 Nov 4

PMID 33147224

Citations 6

Authors

Precil Diego Miranda de Menezes Neves

Rafael A Souza

Fabio M Torres

Fabio A Reis

Rafaela B Pinheiro

Cristiane B Dias

Luis Yu

Viktoria Woronik

Luzia S Furukawa

Livia B Cavalcante

Stanley de Almeida Araujo

David Campos Wanderley

Denise M Malheiros

Lecticia B Jorge

Affiliations

Soon will be listed here.

Abstract

Introduction: IgA nephropathy (IgAN) is the most common primary glomerulopathy worldwide. According to the Oxford Classification, changes in the kidney vascular compartment are not related with worse outcomes. This paper aims to assess the impact of thrombotic microangiopathy (TMA) in the outcomes of Brazilian patients with IgAN.

Materials And Methods: Analysis of clinical data and kidney biopsy findings from patients with IgAN to assess the impact of TMA on renal outcomes.

Results: The majority of the 118 patients included were females (54.3%); mean age of 33 years (25;43); hypertension and hematuria were observed in 67.8% and 89.8%, respectively. Median creatinine: 1.45mg/dL; eGFR: 48.8ml/min/1.73m2; 24-hour proteinuria: 2.01g; low serum C3: 12.5%. Regarding to Oxford Classification: M1: 76.3%; E1: 35.6%; S1: 70.3%; T1/T2: 38.3%; C1/C2: 28.8%. Average follow-up: 65 months. Histologic evidence of TMA were detected in 21 (17.8%) patients and those ones presented more frequently hypertension (100% vs. 61%, p <0.0001), hematuria (100% vs 87.6%, p = 0.0001), worse creatinine levels (3.8 vs. 1.38 mg/dL, p = 0.0001), eGFR (18 vs. 60 ml/min/1.73m2), p = 0.0001), low serum C3 (28.5% vs. 10.4%, p = 0.003), lower hemoglobin levels (10.6 vs. 12.7g/dL, p<0.001) and platelet counts (207,000 vs. 267,000, p = 0.001). Biopsy findings of individuals with TMA revealed only greater proportions of E1 (68% vs. 32%, p = 0.002). Individuals with TMA were followed for less time (7 vs. 65 months, p<0.0001) since they progressed more frequently to chronic kidney disease (CKD) requiring kidney replacement therapy (KRT) (71.4% vs. 21,6%, p<0.0001). Male sex, T1/T2, and TMA were independently associated with progression to CKD-KRT.

Conclusions: In this study patients with TMA had worse clinical manifestations and outcomes. In terms of histologic evidence, E1 distinguished patients with TMA from other patients. Further studies are necessary to analyze the impact of vascular lesions on IgAN prognosis.

Citing Articles

Impact of intrarenal arterial lesions on prognosis of IgA nephropathy: insights from a retrospective cohort study.

Tu J, Chen X, Yang H, Zuo Y, Li F, Zhang J Ren Fail. 2025; 47(1):2476052.

PMID: 40074703 PMC: 11905313. DOI: 10.1080/0886022X.2025.2476052.

Vascular injury in glomerulopathies: the role of the endothelium.

Barbosa G, Camara N, Ledesma F, Duarte Neto A, Dias C Front Nephrol. 2025; 4:1396588.

PMID: 39780910 PMC: 11707422. DOI: 10.3389/fneph.2024.1396588.

Emerging perspectives in the management of IgA nephropathy: a comprehensive review.

Gomes A, Schau B, Farinha A Porto Biomed J. 2024; 9(6):264.

PMID: 39544842 PMC: 11560120. DOI: 10.1097/j.pbj.0000000000000264.

C3 Hypocomplementemia Predicts the Progression of CKD towards End-Stage Kidney Disease in IgA Nephropathy, Irrespective of Histological Evidence of Thrombotic Microangiopathy.

Rossi G, Ricco F, Pisani I, Delsante M, Maggiore U, Fiaccadori E J Clin Med. 2024; 13(9).

PMID: 38731122 PMC: 11084933. DOI: 10.3390/jcm13092594.

Microangiopathy associated with poor outcome of immunoglobulin A nephropathy: a cohort study and meta-analysis.

Dong L, Hu Y, Yang D, Liu L, Li Y, Ge S Clin Kidney J. 2024; 17(2):sfae012.

PMID: 38333627 PMC: 10851670. DOI: 10.1093/ckj/sfae012.

References

Schmitt R, Krmar R, Kristoffersson A, Soderberg M, Karpman D . IgA nephropathy associated with a novel N-terminal mutation in factor H. Eur J Pediatr. 2010; 170(1):107-10. DOI: 10.1007/s00431-010-1279-3. View

Brocklebank V, Wood K, Kavanagh D . Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2017; 13(2):300-317. PMC: 5967417. DOI: 10.2215/CJN.00620117. View

Karoui K, Hill G, Karras A, Jacquot C, Moulonguet L, Kourilsky O . A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol. 2011; 23(1):137-48. PMC: 3269921. DOI: 10.1681/ASN.2010111130. View

DAmico G . Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004; 24(3):179-96. DOI: 10.1016/j.semnephrol.2004.01.001. View

Karoui K, Boudhabhay I, Petitprez F, Vieira-Martins P, Fakhouri F, Zuber J . Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome. Haematologica. 2019; 104(12):2501-2511. PMC: 6959192. DOI: 10.3324/haematol.2019.216903. View

Cavero T, Arjona E, Soto K, Caravaca-Fontan F, Rabasco C, Bravo L . Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome. Kidney Int. 2019; 96(4):995-1004. DOI: 10.1016/j.kint.2019.05.014. View

Timmermans S, Abdul-Hamid M, Vanderlocht J, Damoiseaux J, Reutelingsperger C, van Paassen P . Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. Kidney Int. 2017; 91(6):1420-1425. DOI: 10.1016/j.kint.2016.12.009. View

. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1968; 405:5-37. View

Trimarchi H, Barratt J, Cattran D, Cook H, Coppo R, Haas M . Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017; 91(5):1014-1021. DOI: 10.1016/j.kint.2017.02.003. View

10.

Maixnerova D, Reily C, Bian Q, Neprasova M, Novak J, Tesar V . Markers for the progression of IgA nephropathy. J Nephrol. 2016; 29(4):535-41. PMC: 5548426. DOI: 10.1007/s40620-016-0299-0. View

11.

Bettoni S, Galbusera M, Gastoldi S, Donadelli R, Tentori C, Sparta G . Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis. J Immunol. 2017; 199(3):1021-1040. DOI: 10.4049/jimmunol.1601121. View

12.

Buob D, Decambron M, Gnemmi V, Frimat M, Hoffmann M, Azar R . Collapsing glomerulopathy is common in the setting of thrombotic microangiopathy of the native kidney. Kidney Int. 2016; 90(6):1321-1331. DOI: 10.1016/j.kint.2016.07.021. View

13.

Endo M, Ohi H, Ohsawa I, Matsushita M, Fujita T . Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant. 1998; 13(8):1984-90. DOI: 10.1093/ndt/13.8.1984. View

14.

Gordon C, Chitalia V, Sloan J, Salant D, Coleman D, Quillen K . Thrombotic Microangiopathy: A Multidisciplinary Team Approach. Am J Kidney Dis. 2017; 70(5):715-721. DOI: 10.1053/j.ajkd.2017.05.017. View

15.

Gallan A, Chang A . A New Paradigm for Renal Thrombotic Microangiopathy. Semin Diagn Pathol. 2020; 37(3):121-126. DOI: 10.1053/j.semdp.2020.01.002. View

16.

Roberts I, Cook H, Troyanov S, Alpers C, Amore A, Barratt J . The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009; 76(5):546-56. DOI: 10.1038/ki.2009.168. View

17.

Markiewski M, Nilsson B, Nilsson Ekdahl K, Mollnes T, Lambris J . Complement and coagulation: strangers or partners in crime?. Trends Immunol. 2007; 28(4):184-92. DOI: 10.1016/j.it.2007.02.006. View

18.

Li C, Yap D, Chan G, Wen Y, Li H, Tang C . Clinical Outcomes and Clinico-pathological Correlations in Lupus Nephritis with Kidney Biopsy Showing Thrombotic Microangiopathy. J Rheumatol. 2019; 46(11):1478-1484. DOI: 10.3899/jrheum.180773. View

19.

Goodship T, Cook H, Fakhouri F, Fervenza F, Fremeaux-Bacchi V, Kavanagh D . Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2016; 91(3):539-551. DOI: 10.1016/j.kint.2016.10.005. View

20.

Radhakrishnan J, Perazella M . Drug-induced glomerular disease: attention required!. Clin J Am Soc Nephrol. 2015; 10(7):1287-90. PMC: 4491281. DOI: 10.2215/CJN.01010115. View